JPH11269073A - Preparations containing copper chlorophyllin salts - Google Patents
Preparations containing copper chlorophyllin saltsInfo
- Publication number
- JPH11269073A JPH11269073A JP6821398A JP6821398A JPH11269073A JP H11269073 A JPH11269073 A JP H11269073A JP 6821398 A JP6821398 A JP 6821398A JP 6821398 A JP6821398 A JP 6821398A JP H11269073 A JPH11269073 A JP H11269073A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- salt
- copper chlorophyllin
- preparation
- copper
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、銅クロロフィリン
の塩及び酸を含有してなる製剤に関する。さらに詳しく
は、服用しても口腔内に着色が起きない銅クロロフィリ
ンの塩及び酸を含有する製剤に関する。TECHNICAL FIELD The present invention relates to a preparation containing a salt of copper chlorophyllin and an acid. More specifically, the present invention relates to a preparation containing a salt and an acid of copper chlorophyllin which does not cause coloring in the oral cavity even when taken.
【0002】[0002]
【従来の技術】植物等の葉緑素として天然に常在するク
ロロフィルは、分子内にマグネシウム原子1原子を保持
したポルフィリン系色素で、独特な濃緑色を有すること
が知られる。クロロフィルは脂溶性物質であるが、アル
カリで加水分解することにより水溶性のクロロフィリン
に変換することができる。銅クロロフィリンとは、上記
クロロフィリンの分子中にあるマグネシウム原子を銅原
子に置き換えることにより得られる化合物である。クロ
ロフィリンは、医薬品としては口臭予防や創傷治療に効
果的で、従来から多くの製品に配合されてきた。また、
粘膜保護作用に基づく胃潰瘍、十二指腸潰瘍、胃炎の予
防・治療剤として有用なことでも知られ、極めて身近な
医薬品成分である。このため、通常は、例えば銅クロロ
フィリンカリウム等、塩の形で配合されて、散剤、顆粒
剤、錠剤等、手軽にすぐ服用できる剤形とされる。2. Description of the Related Art Chlorophyll, which is naturally present as chlorophyll in plants and the like, is a porphyrin-based pigment having one magnesium atom in the molecule and is known to have a unique dark green color. Chlorophyll is a fat-soluble substance, but can be converted to water-soluble chlorophyllin by hydrolysis with an alkali. Copper chlorophyllin is a compound obtained by replacing a magnesium atom in the molecule of chlorophyllin with a copper atom. Chlorophylline is effective as a medicine for preventing bad breath and treating wounds, and has been blended in many products. Also,
It is also known to be useful as a prophylactic / therapeutic agent for gastric ulcer, duodenal ulcer and gastritis based on mucosal protection, and is a very familiar pharmaceutical ingredient. For this reason, it is usually compounded in the form of a salt, such as potassium copper chlorophyllin, to give a dosage form that can be taken easily and easily, such as powders, granules and tablets.
【0003】[0003]
【発明が解決しようとする課題】しかし、一方で、銅ク
ロロフィリンカリウムをはじめとする銅クロロフィリン
の塩は濃緑色を呈する物質であるために、それらを含有
する製剤を服用後に口中で溶解した場合は、口腔内、舌
までもが濃緑色に着色するという問題があった。かかる
着色は丸一日もの間舌等に残るほど強力であるため、服
用法は口腔内で溶解しない錠剤等に限られていた。しか
し、消費者のニーズの多様化等から、銅クロロフィリン
の塩を含有した錠剤等を、口中で溶解して服用するチュ
アブル錠のような剤形が剤形が望まれてきた。本発明の
目的は、かかる着色を防止し、かつ服用感に優れた、銅
クロロフィリンの塩を含有してなる製剤を提供すること
である。However, on the other hand, salts of copper chlorophyllin such as potassium copper chlorophyllin are substances showing a dark green color. There is a problem that the oral cavity and even the tongue are colored dark green. Since such coloring is so strong that it remains on the tongue and the like for a whole day, the dosing method has been limited to tablets and the like that do not dissolve in the oral cavity. However, in view of diversification of consumer needs and the like, a dosage form such as a chewable tablet in which a tablet or the like containing a salt of copper chlorophyllin is dissolved and taken in the mouth has been desired. An object of the present invention is to provide a preparation containing a salt of copper chlorophyllin, which prevents such coloring and is excellent in taking feeling.
【0004】[0004]
【課題を解決するための手段】本発明者らは、上記事情
に鑑みて鋭意検討を重ねた結果、銅クロロフィリンの塩
に通常用いられる酸を添加した製剤は、口中で溶解して
も銅クロロフィリンの塩による口腔内、舌の着色を大幅
に軽減することを見出し、本発明を完成するに至った。Means for Solving the Problems The present inventors have conducted intensive studies in view of the above circumstances, and as a result, it has been found that a preparation obtained by adding an acid generally used to a salt of copper chlorophyllin can be dissolved in the mouth even if dissolved in the mouth. The present inventors have found that the coloring of the oral cavity and tongue by the salt of the present invention is greatly reduced, and have completed the present invention.
【0005】即ち、本発明は、銅クロロフィリンの塩及
び酸を含有してなる製剤に関する。また、本発明は、酸
を添加して銅クロロフィリンの塩による口腔内の着色を
防止する方法に関する。That is, the present invention relates to a preparation containing a salt of a copper chlorophyllin and an acid. The present invention also relates to a method for preventing coloring in the oral cavity by a salt of copper chlorophyllin by adding an acid.
【0006】本発明における銅クロロフィリンの塩と
は、銅クロロフィリンが有するカルボキシル基が塩を形
成していることを意味する。かかる塩とは、具体的に例
えば、カリウム塩、ナトリウム塩などのアルカリ金属と
の塩;トリメチルアミン塩、トリエチルアミン塩、プロ
カイン塩、ピリジン塩、フェネチルベンジルアミン塩な
どのアミンとの塩;塩酸塩、臭化水素酸塩、ヨウ化水素
酸塩、硫酸塩、硝酸塩、過塩素酸塩、リン酸塩、炭酸
塩、重炭酸塩などの無機酸との塩;アルギニン酸塩、ア
スパラギン酸塩、グルタミン酸塩、などのアミノ酸との
塩などを意味し、好ましくはカリウム塩、ナトリウム塩
などのアルカリ金属との塩;アルギニン酸塩、アスパラ
ギン酸塩、グルタミン酸塩、などのアミノ酸との塩であ
り、より好ましくはカリウム塩、ナトリウム塩などのア
ルカリ金属との塩である。[0006] The salt of copper chlorophyllin in the present invention means that the carboxyl group of copper chlorophyllin forms a salt. Such salts specifically include, for example, salts with alkali metals such as potassium salt and sodium salt; salts with amines such as trimethylamine salt, triethylamine salt, procaine salt, pyridine salt and phenethylbenzylamine salt; hydrochloride, odor Salts with inorganic acids such as hydrochloride, hydroiodide, sulfate, nitrate, perchlorate, phosphate, carbonate, bicarbonate; alginate, aspartate, glutamate, And the like, preferably a salt with an alkali metal such as a potassium salt or a sodium salt; a salt with an amino acid such as alginate, aspartate, or glutamate, and more preferably potassium. Salts with alkali metals such as salts and sodium salts.
【0007】本発明における酸とは、医薬品添加物とし
て配合可能なあらゆる酸を意味し、具体的には例えば、
塩酸、臭化水素酸、ヨウ化水素酸、硫酸、硝酸、リン
酸、炭酸、重炭酸などの無機酸;酢酸、リンゴ酸、クエ
ン酸、マレイン酸、酒石酸、フマール酸、アスコルビン
酸などの有機カルボン酸;メタンスルホン酸、トリフル
オロメタンスルホン酸、エタンスルホン酸、ベンゼンス
ルホン酸、トルエンスルホン酸などの有機スルホン酸;
アルギニン酸、アスパラギン酸、グルタミン酸などのア
ミノ酸があげられる。The acid in the present invention means any acid that can be compounded as a pharmaceutical excipient, and specifically, for example,
Inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, carbonic acid, bicarbonate; organic carboxylic acids such as acetic acid, malic acid, citric acid, maleic acid, tartaric acid, fumaric acid, ascorbic acid Acids; organic sulfonic acids such as methanesulfonic acid, trifluoromethanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, and toluenesulfonic acid;
Amino acids such as arginic acid, aspartic acid, glutamic acid and the like.
【0008】本発明における銅クロロフィリンの塩と酸
の重量比は、通常、銅クロロフィリンの塩1重量部に対
して前記定義に同じ意味の酸を0.01〜1重量部である
が、好ましくは銅クロロフィリンの塩1重量部に対して
前記定義に同じ意味の酸を0.05〜1重量部、より好まし
くは0.05〜0.75重量部、さらに好ましくは0.1〜0.3重量
部である。In the present invention, the weight ratio of the salt of copper chlorophyllin to the acid is usually 0.01 to 1 part by weight of the acid having the same meaning as defined above with respect to 1 part by weight of the salt of copper chlorophyllin. The acid having the same meaning as defined above is used in an amount of 0.05 to 1 part by weight, more preferably 0.05 to 0.75 part by weight, and even more preferably 0.1 to 0.3 part by weight, per part by weight of the salt.
【0009】更に、本発明にかかる製剤は、銅クロロフ
ィリン塩に他の薬効成分を配合させて製造することもで
きる。当該他の薬効成分は特に限定されず、具体的に例
えば、止しゃ剤、整腸剤、抗潰瘍剤、健胃消化剤、制酸
剤、抗ヒスタミン剤、抗不安剤、抗てんかん剤、解熱鎮
痛消炎剤、利尿剤、血圧降下剤、血管拡張剤、高脂血症
用剤、気管支拡張剤、ビタミン、生薬、抗生物質、抗ウ
イルス剤等があげられる。Further, the preparation according to the present invention can be produced by mixing other medicinal ingredients with copper chlorophyllin salt. The other medicinal components are not particularly limited, and specifically include, for example, an antidepressant, an intestinal suppressant, an anti-ulcer agent, a stomachic digestive agent, an antacid, an antihistamine, an anxiolytic, an antiepileptic, an antipyretic analgesic and antiinflammatory, diuresis. Agents, antihypertensive agents, vasodilators, agents for hyperlipidemia, bronchodilators, vitamins, crude drugs, antibiotics, antiviral agents and the like.
【0010】本発明にかかる製剤は、散剤、顆粒剤、細
粒剤、丸剤、錠剤等の固形製剤;シロップ剤、注射剤等
の液剤等、特に限定されず、製剤であれば何にでも適用
することができる。中でも好ましい剤形は固形製剤で、
とりわけチュアブル錠、トローチ錠等のように口中でか
み砕いたり溶解さすなどして服用する製剤に最適であ
る。The preparations according to the present invention are not particularly limited, such as solid preparations such as powders, granules, fine granules, pills and tablets; liquid preparations such as syrups and injections. Can be applied. Among them, a preferred dosage form is a solid preparation,
It is particularly suitable for preparations such as chewable tablets and lozenges which are chewed or dissolved in the mouth and taken.
【0011】これらの製剤化には通常用いられる種々の
添加剤を配合することができる。かかる添加剤として
は、固形製剤の場合、例えば、賦形剤、結合剤、滑沢
剤、着色剤、矯味矯臭剤等があげられ、必要により、吸
収促進剤、界面活性剤抗酸化剤などを使用することもで
きる。また、液剤の場合に配合可能な添加剤としては、
例えば、界面活性剤、乳化剤、懸濁化剤、保存剤、安定
化剤、吸収促進剤、溶解補助剤、pH調製剤、防腐剤、
抗酸化剤等があげられる。For the preparation of these preparations, various additives commonly used can be blended. Examples of such additives include, in the case of solid preparations, excipients, binders, lubricants, coloring agents, flavoring agents, and the like.If necessary, absorption enhancers, surfactants, antioxidants, etc. Can also be used. In addition, as an additive that can be blended in the case of a liquid,
For example, surfactants, emulsifiers, suspending agents, preservatives, stabilizers, absorption enhancers, solubilizers, pH adjusters, preservatives,
And antioxidants.
【0012】本発明にかかる製剤は、固形製剤、液剤等
いずれの場合においても、通常の製剤化の方法で製造す
ることができる。例えば、固形製剤であれば、銅クロロ
フィリンの塩及び酸を必要に応じて乳糖、マンニトール
等の賦形剤を添加して混合し、ポリビニルピロリドン、
ヒドロキシプロピルセルロース等の結合剤を加えて、押
出し造粒、流動層造粒又は噴霧乾燥式造粒等により造
粒、乾燥し、顆粒剤とすることができ、その後これを通
常の方法により、チュアブル錠等とすることもできる。The preparation according to the present invention can be produced by a usual preparation method in any case such as a solid preparation and a liquid preparation. For example, in the case of a solid preparation, a salt and an acid of copper chlorophyllin are added and mixed with an excipient such as lactose and mannitol as needed, and polyvinylpyrrolidone,
A binder such as hydroxypropylcellulose is added, and the mixture can be granulated by extrusion granulation, fluidized-bed granulation or spray-drying granulation and dried to obtain granules, which are then chewable by a usual method. Tablets and the like can also be used.
【0013】[0013]
【実施例】以下に、実施例及び試験例を示して本発明を
さらに詳細に説明するが、本発明がこれらに限定される
ものでないことはいうまでもない。The present invention will be described in more detail with reference to examples and test examples below, but it goes without saying that the present invention is not limited to these examples.
【0014】実施例1銅クロロフィリンカリウム及びクエン酸を配合した顆粒
剤 水酸化マグネシウム60g、沈降炭酸カルシウム110g、無
水リン酸水素カルシウム120g、銅クロロフィリンカリウ
ム9g、精製白糖21g、乳糖121.2g、アスパルテーム1g、
ステアリン酸マグネシウム10g、無水クエン酸9gを撹拌
混合し、粉状固形製剤を得た。かかる粉状固形製剤を乾
燥後、1-メントール0.8gを投入して撹拌混合し、顆粒剤
462gを得た。Example 1 Granules containing potassium copper chlorophyllin and citric acid
Agent magnesium hydroxide 60 g, precipitated calcium carbonate 110g, calcium hydrogen phosphate anhydrous 120 g, copper chlorophyllin potassium 9 g, purified sucrose 21g, lactose 121.2 g, aspartame 1g,
10 g of magnesium stearate and 9 g of anhydrous citric acid were stirred and mixed to obtain a powdery solid preparation. After drying such a powdered solid preparation, 0.8 g of 1-menthol is added, and the mixture is stirred and mixed.
462 g were obtained.
【0015】実施例2銅クロロフィリンカリウム及びクエン酸を配合したチュ
アブル錠 水酸化マグネシウム60g、沈降炭酸カルシウム110g、無
水リン酸水素カルシウム120g、銅クロロフィリンカリウ
ム9g、精製白糖21g、乳糖121.2g、アスパルテーム1g、
無水クエン酸9gを撹拌混合し、粉状固形製剤を得た。か
かる粉状固形製剤を乾燥後、ステアリン酸マグネシウム
10g、1-メントール0.8gを投入して撹拌混合し、打錠成
形によりチュアブル錠を得た。Example 2 A tube containing potassium copper chlorophyllin and citric acid
Able tablets 60 g magnesium hydroxide, precipitated calcium carbonate 110 g, anhydrous calcium hydrogen phosphate 120 g, copper chlorophyllin potassium 9 g, purified sucrose 21 g, lactose 121.2 g, aspartame 1 g,
9 g of citric anhydride was stirred and mixed to obtain a powdery solid preparation. After drying such a powdered solid preparation, magnesium stearate
10 g and 1 g of 1-menthol were added and mixed by stirring, and a chewable tablet was obtained by tableting.
【0016】対照例 実施例2に記載の処方から無水クエン酸を除いて、同様
の方法によりチュアブル錠を製造し、対照例とした。Control Example A chewable tablet was produced in the same manner as in Example 2 except that citric anhydride was omitted from the formulation described in Example 2, and this was used as a control.
【0017】[0017]
【試験例】前記の実施例2と対照例で得られた錠剤それ
ぞれ1錠を被験者20名が空腹時に口腔内でかみ砕かずに
溶解し、溶解直後と、10分経過後の2回、被験者の舌の
着色の度合いを観察した。結果を表1に示す。[Test Example] Twenty test subjects dissolved one tablet obtained in each of the above Example 2 and the control example without chewing in the oral cavity on an empty stomach. The degree of coloring of the tongue was observed. Table 1 shows the results.
【0018】[0018]
【表1】 [Table 1]
【0019】[0019]
【発明の効果】本発明は、銅クロロフィリンの塩と酸を
含有することを特徴とする製剤であり、特に、口腔内で
溶解後の銅クロロフィリンの塩による舌、口腔内の着色
を効果的に防止できる点で優れている。Industrial Applicability The present invention is a preparation containing a salt of copper chlorophyllin and an acid. In particular, it effectively discolors the tongue and the oral cavity by the salt of copper chlorophyllin after dissolving in the oral cavity. It is excellent in that it can be prevented.
【0020】上記した効果から、本発明により、銅クロ
ロフィリンの塩を含有し、かつ着色を気にせずいつでも
気軽に服用可能な製剤を提供することができる。From the above effects, according to the present invention, it is possible to provide a preparation containing a salt of copper chlorophyllin, which can be easily taken at any time without regard to coloring.
フロントページの続き (51)Int.Cl.6 識別記号 FI A61K 47/12 A61K 47/12 Z Continued on the front page (51) Int.Cl. 6 Identification code FI A61K 47/12 A61K 47/12 Z
Claims (7)
る製剤。1. A preparation comprising a salt of a copper chlorophyllin and an acid.
る固形製剤。2. A solid preparation comprising a salt of copper chlorophyllin and an acid.
カリウム又は銅クロロフィリンナトリウムである請求項
1又は2記載の製剤。3. The preparation according to claim 1, wherein the salt of copper chlorophyllin is potassium copper chlorophyllin or sodium copper chlorophyllin.
酸、リンゴ酸、塩酸又はリン酸から選ばれる1種以上の
酸である請求項1ないし3のいずれか1項に記載の製
剤。4. The preparation according to any one of claims 1 to 3, wherein the acid is at least one acid selected from ascorbic acid, tartaric acid, citric acid, malic acid, hydrochloric acid and phosphoric acid.
を0.1重量部〜10重量部含有してなる請求項1又は
2記載の製剤。5. The preparation according to claim 1, comprising 0.1 to 10 parts by weight of an acid per 1 part by weight of the salt of copper chlorophyllin.
るチュアブル錠。6. A chewable tablet comprising a copper chlorophyllin salt and an acid.
舌の着色を防止する方法。7. A method for preventing tongue coloring by a salt of copper chlorophyllin by adding an acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP06821398A JP3734360B2 (en) | 1998-03-18 | 1998-03-18 | Formulation containing a salt of copper chlorophyllin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP06821398A JP3734360B2 (en) | 1998-03-18 | 1998-03-18 | Formulation containing a salt of copper chlorophyllin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH11269073A true JPH11269073A (en) | 1999-10-05 |
| JP3734360B2 JP3734360B2 (en) | 2006-01-11 |
Family
ID=13367304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP06821398A Expired - Fee Related JP3734360B2 (en) | 1998-03-18 | 1998-03-18 | Formulation containing a salt of copper chlorophyllin |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3734360B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2023190849A1 (en) * | 2022-03-31 | 2023-10-05 | ||
| CN117100756A (en) * | 2015-01-19 | 2023-11-24 | C·V·萨万基卡尔 | Chlorophylin compositions and uses thereof |
-
1998
- 1998-03-18 JP JP06821398A patent/JP3734360B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117100756A (en) * | 2015-01-19 | 2023-11-24 | C·V·萨万基卡尔 | Chlorophylin compositions and uses thereof |
| JPWO2023190849A1 (en) * | 2022-03-31 | 2023-10-05 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3734360B2 (en) | 2006-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU609988B2 (en) | Pharmaceutical compositions | |
| JP4346817B2 (en) | Oral preparation | |
| JP2735903B2 (en) | Ibuprofen boiling formulation | |
| US9492551B2 (en) | Orally administrable gallium compositions and methods of use | |
| KR100408587B1 (en) | Pharmaceutical composition for oral administration | |
| KR100408582B1 (en) | Pharmaceutical composition for oral administration | |
| HRP931049A2 (en) | Taste-masking composition of bitter pharmaceutical agents | |
| HU195617B (en) | Process for producing pharmaceutical compositions containing 2-/4-isobutyl-phenyl6-propionic acid | |
| JPS5920230A (en) | Drug containing piruprophen | |
| CA2381580A1 (en) | Process for manufacturing a pharmaceutical chewing gum | |
| JP4300652B2 (en) | Oral solid formulation | |
| JPH06211672A (en) | Antacid | |
| US3865935A (en) | Tableting of erythromycin base | |
| FI120080B (en) | Pharmaceutical compositions with antibiotic activity | |
| JPH02270827A (en) | Anti-ulcer composite | |
| DE69718077T2 (en) | Medicines consisting of diclofenac | |
| CN1065128C (en) | Amino acid metal chelate and its preparation and preparing method | |
| RU2065300C1 (en) | Pharmaceutical composition as carbonated tablet | |
| JPH11269073A (en) | Preparations containing copper chlorophyllin salts | |
| JP2003221326A (en) | Chewable agent containing branched amino acids | |
| JPH0656677A (en) | Antacid composition | |
| DE3922441A1 (en) | IBUPROFEN AND S - (+) - IBUPROFEN PREPARATIONS AND METHOD FOR THEIR PRODUCTION | |
| JPH10203963A (en) | Pharmaceutical composition for oral administration containing bactericidal substance and mucoadhesive substance | |
| JP2809301B2 (en) | Orally administered drug with bitterness masked | |
| JP2004231546A (en) | Antipyretic analgesic composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040302 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20041019 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041118 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041217 |
|
| A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20050525 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050704 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050714 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20050714 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20051004 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20051018 |
|
| R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313115 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091028 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101028 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111028 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121028 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131028 Year of fee payment: 8 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |